Answers are grounded in this paper and cite their sources.
The scale will support a standardised approach to assessing the social and behavioural aspects of MAP vaccines, enabling comparison of outcomes across studies. Once validated, this scale will assist vaccination programmes in developing effective strategies for integrating MAPs and overcoming barriers to vaccination. This includes improving vaccine equity and accessibility, especially in lower- and middle-income countries and rural or remote locations.
No takes yet. Share an insight, caveat, or question.
Berger et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: